Overview
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Indication
For the treatment of pulmonary tuberculosis.
Associated Conditions
- Active Tuberculosis
- Late phase Tuberculosis
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/04/08 | Phase 2 | Not yet recruiting | Shandong University | ||
2025/03/13 | Phase 4 | Active, not recruiting | |||
2024/02/28 | Phase 1 | Recruiting | |||
2024/02/12 | Phase 3 | Recruiting | |||
2024/01/05 | Phase 3 | Not yet recruiting | |||
2022/07/12 | Phase 3 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | ||
2021/11/16 | Phase 1 | Recruiting | The Aurum Institute NPC | ||
2021/08/25 | Phase 4 | Not yet recruiting | Miguel Santín | ||
2021/01/11 | Phase 4 | Completed | |||
2020/09/16 | Phase 4 | Withdrawn |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| RPK Pharmaceuticals, Inc. | 53002-1718 | ORAL | 150 mg in 1 1 | 7/6/2018 | |
| A-S Medication Solutions | 50090-5063 | ORAL | 150 mg in 1 1 | 7/6/2018 | |
| sanofi-aventis U.S. LLC | 0088-2102 | ORAL | 150 mg in 1 1 | 7/6/2018 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Rifapentine Capsules | 国药准字H10940211 | 化学药品 | 胶囊剂 | 12/14/2020 | |
| Rifapentine Capsules | 国药准字H20133047 | 化学药品 | 胶囊剂 | 7/28/2022 | |
| Rifapentine Capsules | 国药准字H10940212 | 化学药品 | 胶囊剂 | 12/18/2020 | |
| Rifapentine Capsules | 国药准字H10940011 | 化学药品 | 胶囊剂 | 7/23/2020 | |
| Rifapentine Capsules | 国药准字H20093872 | 化学药品 | 胶囊剂 | 6/21/2019 | |
| Rifapentine Capsules | 国药准字H10940199 | 化学药品 | 胶囊剂 | 12/4/2019 | |
| Rifapentine Capsules | 国药准字H10940012 | 化学药品 | 胶囊剂 | 7/23/2020 | |
| Rifapentine Capsules | 国药准字H10840004 | 化学药品 | 胶囊剂 | 3/22/2024 | |
| Rifapentin Dispersible Tablets | 国药准字H20120045 | 化学药品 | 片剂 | 1/18/2022 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.